NASDAQ:GLUE Monte Rosa Therapeutics Q2 2026 Earnings Report $12.13 -0.47 (-3.73%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$12.24 +0.11 (+0.95%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Monte Rosa Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.38Beat/MissMissed by -$0.05One Year Ago EPSN/AMonte Rosa Therapeutics Revenue ResultsActual Revenue$8.97 millionExpected Revenue$12.91 millionBeat/MissMissed by -$3.95 millionYoY Revenue GrowthN/AMonte Rosa Therapeutics Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time7:00AM ETUpcoming EarningsMonte Rosa Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monte Rosa Therapeutics Earnings HeadlinesWedbush Reiterates "Outperform" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)September 11, 2026 | americanbankingnews.comMonte Rosa to Receive $50 Million Milestone Payment From Novartis for Phase 2 Launch of MRT-6160September 8, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)September 8, 2026 | globenewswire.comMonte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance SheetSeptember 3, 2026 | seekingalpha.comMonte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2026 | globenewswire.comSee More Monte Rosa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monte Rosa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monte Rosa Therapeutics and other key companies, straight to your email. Email Address About Monte Rosa TherapeuticsMonte Rosa Therapeutics (NASDAQ:GLUE) is a clinical-stage biotechnology company developing small-molecule medicines designed to selectively eliminate disease-causing proteins. The company uses its proprietary Tunable Molecular Glue (TME) platform to identify molecular glue degraders that redirect the cell’s natural protein-degradation machinery toward specific therapeutic targets. Monte Rosa’s research and development programs address areas including autoimmune and inflammatory diseases, as well as cancer. Its pipeline has included MRT-6160, an orally administered molecular glue degrader designed to target VAV1, a protein involved in immune-cell signaling, and MRT-2359, a degrader targeting GSPT1 for potential use in oncology. The company continues to evaluate and advance its most promising programs through clinical development. Founded in 2018 and headquartered in Boston, Massachusetts, Monte Rosa conducts drug discovery and clinical-development activities through operations and collaborations serving the global biopharmaceutical market. The company’s common stock trades on the Nasdaq under the symbol GLUE.View Monte Rosa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
